Janel Buys EnCor Biotechnology for $17M Base Price, Funds $11.96M Cash with Expanded Credit Line
JANL has more than doubled off its 52-week low of $21 on light trading volume (0.3× avg).
Summary
Janel closed its acquisition of EnCor Biotechnology for a $17,000,000 base price, paying $11,960,000 in cash and a $5,040,000 subordinated note, funded partly by an $11,000,000 draw on an expanded $15,000,000 acquisition facility.
Key Events · M&A and Partnerships · JANL
-
EnCor Biotechnology Acquired
Antibodies Incorporated, a wholly owned Janel subsidiary, bought 100% of EnCor Biotechnology Inc. on October 20, 2026 for a $17,000,000 base purchase price, subject to a working capital adjustment.
-
Cash and Note Consideration
Closing consideration was $11,960,000 in cash plus a $5,040,000 subordinated promissory note; seller Gerry Shaw also receives $1,680,000 on each of the first three anniversaries of closing.
-
Credit Facility Upsized
The Second Amendment to the senior credit agreement added a $15,000,000 incremental acquisition commitment, $11,000,000 of which was immediately funded for the EnCor cash consideration, and added an excess cash flow mandatory prepayment provision.
-
Target Financials May Be Omitted
Janel is requesting SEC relief from Rule 3-05 audited financial statements and Rule 11-01 pro forma information for EnCor, arguing they would not be material to stockholders; the SEC is still considering the request.
Analysis · JANL · Trade & Services
Janel's Antibodies Incorporated subsidiary has closed on 100% of EnCor Biotechnology, a Gainesville, Florida antibody and reagent maker focused on neurological disease research. The $17,000,000 base price breaks into $11,960,000 of cash at closing and a $5,040,000 subordinated note, with another $5,040,000 in deferred payments to seller Gerry Shaw spread over the first three anniversaries. Funding came from operations plus an $11,000,000 draw on a newly upsized $15,000,000 acquisition facility under the Santander-led senior credit agreement, which also added an excess cash flow sweep. That sweep directs future free cash to debt reduction first, constraining the balance sheet flexibility the company had after its Q3 cash build. At roughly a quarter of Janel's market value, the deal is a real step-up in scale for the antibody business rather than a bolt-on rounding error. Investors will not get standalone target financials unless the SEC refuses the company's request to waive audited EnCor financials.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 38.5% of the 1020 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JANL was trading at $48.00 on OTC in the Trade & Services sector, with a market capitalization of approximately $56.9M. The 52-week trading range was $21.00 to $62.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.